Ocular Therapeutix (OCUL) Other Non Operating Income (2013 - 2026)
Ocular Therapeutix (OCUL) posted quarterly Other Non Operating Income of $689000.0 for Q2 2026, up 207.49% year-over-year from $224073.6 in Q2 2025, and down 52.65% on a QoQ basis from $1.5 million in Q1 2026.
Ocular Therapeutix (OCUL) Other Non Operating Income (2013 - 2026) Analysis & Trends
Ocular Therapeutix has reported Other Non Operating Income for 13 years, with the latest figure at $689000.0 in Q2 2026.
- Other Non Operating Income for Q2 2026 came in at $689000.0, up 207.49% year-over-year; the trailing twelve-month figure through Jun 2026 was $1.3 million (down 76.32% YoY), and the FY2025 annual result was -$2.5 million, up 91.16% from the prior year.
- Other Non Operating Income fell to $689000.0 in Q2 2026, from $1.5 million in the prior quarter.
- Over five years, Other Non Operating Income peaked at $14.2 million in Q3 2023 and troughed at -$28.0 million in Q1 2024.
- A 5-year average of -$101812.5 and a median of $642000.0 in 2025 frame the typical range for Other Non Operating Income.
- The widest annual swing landed in 2023, when Other Non Operating Income soared 1352.43%; it then plunged 367.64% in 2024.
- A 5-year view of Other Non Operating Income shows it stood at $5.2 million in 2022, then surged by 170.65% to $14.2 million in 2023, then slumped by 50.13% to $7.1 million in 2024, then sank by 91.59% to $595000.0 in 2025, then climbed by 15.8% to $689000.0 in 2026.
- Per Business Quant data, the three most recent Other Non Operating Income figures were $689000.0 in Q2 2026, $1.5 million in Q1 2026, and $595000.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Ocular Therapeutix | 2.20 Bn | 2.20 Bn | 11.46 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 689,000.00 |
| Mar 31, 2026 | 1.46 Mn |
| Dec 31, 2025 | 595,000.00 |
| Sep 30, 2025 | -1.45 Mn |
| Jun 30, 2025 | -641,000.00 |
| Mar 31, 2025 | -978,000.00 |
| Sep 30, 2024 | 7.08 Mn |
| Jun 30, 2024 | -3.03 Mn |
| Mar 31, 2024 | -27.95 Mn |
| Dec 31, 2023 | 12.90 Mn |
| Sep 30, 2023 | 6.72 Mn |
| Jun 30, 2023 | 1.13 Mn |
| Mar 31, 2023 | -6.56 Mn |
| Dec 31, 2022 | 5.24 Mn |
| Sep 30, 2022 | -1.13 Mn |
| Jun 30, 2022 | 2.77 Mn |
| Mar 31, 2022 | 6.96 Mn |
| Dec 31, 2021 | -62.25 Mn |
| Sep 30, 2021 | 23.84 Mn |
| Jun 30, 2021 | 13.40 Mn |